Skip to main content
padlock icon - secure page this page is secure

TNF alpha Inhibition as Treatment Modality for Certain Rheumatologic and Gastrointestinal Diseases

Buy Article:

$68.00 + tax (Refund Policy)

With the development of biologicals that specifically target tumor necrosis factor (TNF)α, our therapeutic approach to inflammatory diseases has dramatically changed. There are currently three anti-TNFα drugs available: etanercept, infliximab, and adalimumab.

Etanercept is a recombinant fusion protein that can be used alone or in combination with other medications for conditions such as rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, psoriasis, and ankylosing spondylitis. Infliximab, a chimeric humanized monoclonal antibody and adalimumab, a fully human monoclonal antibody are approved for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, and moderate to severe Crohn's disease. Infliximab is also approved for ulcerative colitis, adalimumab for juvenile rheumatoid arthritis. Another anti-TNFα drug, certolizumab pegol, was declined EMEA approval as treatment option for active Crohn's disease . However, in the USA it was approved by the FDA to treat moderate to severely active Crohn's disease in adults who have not been helped by usual treatments (April 2008) in addition to the treatment of moderately to severely active rheumatoid arthritis (May 2009).

It is the goal of this review article to summarize various therapeutic indications, underlying studies, safety, and use during pregnancy, as well as future directions for anti-TNF therapies.

No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Crohn's disease; Tumor necrosis factor (TNF); adalimumab; ankylosing spondylitis; etanercept; infliximab; psoriatic arthritis; rheumatoid arthritis; ulcerative colitis

Document Type: Research Article

Publication date: September 1, 2009

More about this publication?
  • This journal is devoted to timely reviews of experimental and clinical studies in the field of endocrine, metabolic, and immune disorders. Specific emphasis is placed on humoral and cellular targets for natural, synthetic, and genetically engineered drugs that enhance or impair endocrine, metabolic, and immune parameters and functions. Topics related to the neuroendocrine-immune axis are given special emphasis in view of the growing interest in stress-related, inflammatory, autoimmune, and degenerative disorders.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more